The clinical effectiveness of probiotics and autoprobiotics in treatment of Helicobacter pylori-associated dyspepsia
- Authors: Ermolenko E.I.1,2, Molostova A.S.1,3, Baryshnikova N.V.1,4,5, Svarval A.V.6, Gladyshev N.S.6,7, Kashchenko V.A.7,3, Suvorov A.N.1,7
-
Affiliations:
- Institute of Experimental Medicine
- North-Western State Medical University named after I.I. Mechnikov
- North-Western District Scientific and Clinical Center named after L.G. Sokolov, Federal Medical and Biological Agency
- Pavlov First Saint Petersburg State Medical University
- St. Petersburg State Pediatric Medical University
- St. Petersburg Pasteur Institute
- St. Petersburg State University
- Issue: Vol 12, No 4 (2022)
- Pages: 726-734
- Section: ORIGINAL ARTICLES
- URL: https://ogarev-online.ru/2220-7619/article/view/119093
- DOI: https://doi.org/10.15789/2220-7619-TCE-1927
- ID: 119093
Cite item
Full Text
Abstract
The aim of our study was to evaluate the clinical performance of a monotherapy by Enterococcus faecium-based probiotics and indigenous autoprobiotics against H. pylori associated dyspepsia.
Materials and methods. There were examined 95 patients with dyspepsia. The entire patient cohort underwent clinical evaluation including filling out the questionnaire to assess dyspepsia symptoms before and after treatment, gastric endoscopy as well as gastric multi-focal biopsy (gastric body and gastric antrum) and verification of H. pylori infection with the three clinical laboratory methods (biochemical, bacteriological and molecular detection). An antagonistic in vitro activity of probiotics against H. pylori was detected by drop plate method for probiotic strains Enterococcus faecium SF68 and Bifidobacterium bifidum (Bifiform), Enterococcus faecium L3 (Laminolact), and autoprobiotic strains combined with indigenous Enterococcus faecium. To examine an antagonistic activity of probiotics and autoprobiotics in clinical trials, we used a starter culture based on the Enterococcus faecium L3 strain and an autoprobiotic based on indigenous Enterococcus faecium. The probiotic or autoprobiotic were administered orally to patients with gastritis twice a day at dose of 50 ml (8.0 lgCFU/ml) for 20 days. H. pylori eradication was assessed by stool antigen test 1.5–2 months after the end of treatment.
Results. Initially the H. pylori infection was confirmed with 49.4% of patients. The sensitivity of H. pylori to the probiotics was detected in 81% of individuals for indigenous Enterococci (the autoprobiotic), 76% — for Laminolact, and in 62% — for Bifiform. 22 patients with previous history of allergic reactions to antibiotics used in routine H. pylori eradication regimens were divided in two cohorts. One cohort (10 patients) received the autoprobiotic only, another cohort (12 patients) received only probiotic. Monotherapy with autoprobiotic resulted in 100% H. pylori eradication, single-agent therapy with probiotic led to 60% eradication of H. pylori. Dyspepsia symptoms were completely resolved in both groups of patients.
Conclusion. Our research demonstrated the sensitivity of examined H. pylori strains to be similar for traditional eradication treatment agents (antibiotics) and the proposed intervention agents (probiotics and autoprobiotics). An autoprobiotic monotherapy with indigenous enterococci led to higher levels of H. pylori eradication than with E. faecium L3-based probiotic agent. Our work demonstrated advantage for application of probiotics in patients with antibiotic allergies or other obstacles for the standard eradication therapy. Nonetheless, further investigation to better understand underlying mechanisms of action, as well as larger observational and randomized studies, are necessary to determine the scope of therapeutic application for probiotics and autoprobitics to eradicate H. pylori infection.
Full Text
##article.viewOnOriginalSite##About the authors
Elena I. Ermolenko
Institute of Experimental Medicine; North-Western State Medical University named after I.I. Mechnikov
Email: lermolenko1@yandex.ru
д.м.н., зав. лабораторией биомедицинской микроэкологии отдела молекулярной микробиологии, профессор кафедры медицинской микробиологии
Russian Federation, St. Petersburg; St. PetersburgAnastasiya S. Molostova
Institute of Experimental Medicine; North-Western District Scientific and Clinical Center named after L.G. Sokolov, Federal Medical and Biological Agency
Email: ana15951@yandex.ru
врач-гастроэнтеролог, младший научный сотрудник
Russian Federation, St. Petersburg; St. PetersburgNatalia V. Baryshnikova
Institute of Experimental Medicine; Pavlov First Saint Petersburg State Medical University; St. Petersburg State Pediatric Medical University
Email: baryshnikova_nv@mail.ru
ORCID iD: 0000-0001-7429-0336
к.м.н., доцент, научный сотрудник лаборатории молекулярной микробиологии, доцент кафедры внутренних болезней стоматологического факультета, младший научный сотрудник лаборатории медико-социальных проблем педиатрии
Russian Federation, St. Petersburg; St. Petersburg; St. PetersburgAlena V. Svarval
St. Petersburg Pasteur Institute
Author for correspondence.
Email: alenasvar@rambler.ru
ORCID iD: 0000-0001-9340-4132
к.м.н., старший научный сотрудник, зав. лабораторией идентификации патогенов
Russian Federation, 14, Mira str., St. Petersburg, 197101Nikita S. Gladyshev
St. Petersburg Pasteur Institute; St. Petersburg State University
Email: krinege@mail.ru
Scopus Author ID: 57221052753
ResearcherId: S-9158-2018
лаборант лаборатории идентификации патогенов, студент образовательной программы «Лечебное дело» медицинского факультета
Russian Federation, 14, Mira str., St. Petersburg, 197101; St. PetersburgVictor A. Kashchenko
St. Petersburg State University; North-Western District Scientific and Clinical Center named after L.G. Sokolov, Federal Medical and Biological Agency
Email: surg122@yandex.ru
д.м.н., профессор, зав. кафедрой факультетской хирургии, зам. генерального директора по научно-образовательной работе, главный хирург
Russian Federation, St. Petersburg; St. PetersburgAlexander N. Suvorov
Institute of Experimental Medicine; St. Petersburg State University
Email: alexander_suvorov1@hotmail.com
ORCID iD: 0000-0003-2312-5589
член-корреспондент РАН, д.м.н., профессор, зав. отделом молекулярной микробиологии, зав. кафедрой фундаментальных проблем медицины и медицинских технологий факультета стоматологии и медицинских технологий
Russian Federation, St. Petersburg; St. PetersburgReferences
- Боровкова Е.А., Алиева Е.В. Микробиологическое исследование микрофлоры толстого кишечника на дисбактериоз в оценке эффективности аутопробиотикотерапии // Естественные и технические науки. 2020. Т. 8, № 146. С. 24–33. [Borovkova E.A., Alieva E.V. Microbiological examination of the microflora of the large intestine for dysbacteriosis in assessing the effectiveness of autoprobiotic therapy. Estestvennye i tekhnicheskie nauki = Natural and Technical Sciences, 2020, vol. 8, no. 146, pp. 24–33. (In Russ.)]
- Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Дехнич Н.Н., Козлов Р.С., Кляритская И.Л., Корочанская Н.В., Курилович С.А., Осипенко М.Ф., Симаненков В.И., Ткачев А.В., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018. Т. 28, № 1. С. 55–70. [Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya Y.K., Abdulkhakov R.A., Alekseyeva O.P., Alekseyenko S.A., Dekhnich N.N., Kozlov R.S., Klyaritskaya I.L., Korochanskaya N.V., Kurilovich S.A., Osipenko M.F., Simanenkov V.I., Tkachev A.V., Khlynov I.B., Tsukanov V.V. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2018, vol. 28, no. 1, pp. 55–70. (In Russ.)] doi: 10.22416/1382-4376-2018-28-1-55-70
- Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И., Абдулхаков Р.А., Абдулхаков С.Р., Авалуева Е.Б., Ардатская М.Д., Ахмедов В.А., Бордин Д.С., Бурков С.Г., Бутов М.А., Голованова Е.В., Голофеевский В.Ю., Гриневич В.Б., Джулай Г.С., Добрица В.П., Еремина Е.Ю., Жигалова Т.Н., Иваников И.О., Исаков В.А., Казюлин А.Н., Калинин А.В., Козлова И.В., Комиссаренко И.А., Корниенко Е.А., Корочанская Н.В., Курилович С.А., Кучерявый Ю.А., Ли Е.Д., Ли И.А., Левченко С.В., Ливзан М.А., Логинов А.Ф., Лоранская И.Д., Маев И.В., Максимов В.А., Миллер Д.А., Минушкин О.Н., Низов А.А., Орешко Л.С., Осипенко М.Ф., Пальцев А.И., Пасечников В.Д., Радченко В.Г., Рустамов М.Н., Саблин О.А., Сагынбаева В.Э., Сайфутдинов Р.Г., Самсонов А.А., Сарсенбаева А.С., Селиверстов П.В., Симаненков В.И., Ситкин С.И., Старостин Б.Д., Суворов А.Н., Тарасова Л.В., Ткачев А.В., Успенский Ю.П., Хлынова О.В., Хомерики Н.М., Хомерики С.Г., Цуканов В.В., Чернин В.В., Чернышев А.Л., Шархун О.О., Щербаков П.Л., Яковенко Э.П. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения) // Экспериментальная и клиническая гастроэнтерология. 2017. № 2. С. 3–21. [Lazebnik L.B., Tkachenko E.I., Abdulganiyeva D.I., Abdulkhakov R.A., Abdulkhakov S.R., Avaluyeva E.B., Ardatskaya M.D., Akhmedov V.A., Bordin D.S., Burkov S.G., Butov M.A., Golovanova E.V., Golofeyevskiy V.Yu., Grinevich V.B., Dzhulay G.S., Dobritsa V.P., Eremina E.Yu., Zhigalova T.N., Ivanikov I.O., Isakov V.A., Kazyulin A.N., Kalinin A.V., Kozlova I.V., Komissarenko I.A., Kornienko E.A., Korochanskaya N.V., Kurilovich S.A., Kucheryavyy Yu.A., Li E.D., Li I.A., Levchenko S.V., Livzan M.A., Loginov A.F., Loranskaya I.D., Mayev I.V., Maksimov V.A., Miller D.A., Minushkin O.N., Nizov A.A., Oreshko L.S., Osipenko M.F., Pal’tsev A.I., Pasechnikov V.D., Radchenko V.G., Rustamov M.N., Sablin O.A., Sagynbayeva V.E., Sayfutdinov R.G., Samsonov A.A., Sarsenbayeva A.S., Seliverstov P.V., Simanenkov V.I., Sitkin S.I., Starostin B.D., Suvorov A.N., Tarasova L.V., Tkachev A.V., Uspenskiy Yu.P., Khlynova O.V., Khomeriki N.M., Khomeriki S.G., Tsukanov V.V., Chernin V.V., Chernyshev A.L., Sharkhun O.O., Scherbakov P.L., Yakovenko E.P. VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter pylori-associated diseases (VI Moscow agreement). Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology, 2017, no. 2, pp. 3–21. (In Russ.)]
- Симаненков В.И., Захарова Н.В., Жебрун А.Б., Сварваль А.В., Савилова И.В., Ферман Р.С. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования // Лечащий врач. 2015. № 4: 91. [SimanenkovV.I., ZakharovaN.V., ZhebrunA.B., Svarval’ A.V., SavilovaI.V., FermanR.S. Resistance of Helicobacter pylori to antimicrobial preparations by the results of bacteriologic testing. Lechashchii vrach = Lechashchii Vrach, 2015, no. 4: 91. (In Russ.)] URL: https://www.lvrach.ru/2015/04/15436214
- Патент № 2546253 Российская Федерация, МПК C12N 1/20 (2006.01), C12Q 1/68 (2006.01), A61K 35/74 (2015.01), A23C 9/123 (2006.01). Способ получения персонифицированного аутопробиотического продукта и способ лечения синдрома раздраженного кишечника с использованием этого продукта; № 2013120765/10; заявлено 25.04.2013: опубликовано: 10.04.2015 / Симаненков В.И., Суворов А.Н., Соловьева О.И., Ермоленко Е.И., Цапиева А.Н., Сундукова З.Р. Патентообладатель: Симаненков В.И., Суворов А.Н. 23 с. [Patent No. 2546253 Russian Federation, Int. C12N 1/20 (2006.01), C12Q 1/68 (2006.01), A61K 35/74 (2015.01), A23C 9/123 (2006.01). Method of obtaining personified autoprobioticproduct and method of treating syndrome of irritable bowl with thereof application. No. 2013120765/10; application: 25.04.2013: date of publication 10.04.2015 / Simanenkov V.I., Suvorov A.N., Solov’eva O.I., Ermolenko E.I., Tsapieva A.N., Sundukova Z.R. Proprietors: Simanenkov V.I., Suvorov A.N. 23 p.]
- Суворов А.Н., Барышникова Н.В., Сварваль А.В., Ниязов Р.М. Возможности некоторых пробиотических штаммов в эрадикации Helicobacter pylori in vitro и in vivo // Фарматека. 2018. № 2. С. 74–78. [Suvorov A.N., Baryshnikova N.V., Svarval A.V., Niyazov R.M. Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo. Farmateka = Pharmateca, 2018, no. 2, pp. 74–78. (In Russ.)]
- Ткаченко Е.И., Успенский Ю.П., Барышникова Н.В. Оптимизация лечения заболеваний, ассоциированных с Helicobacter pylori // Врач. 2012. no. 1, pp. 36–38. [Tkachenko E., Uspenskiy Yu., Baryshnikova N. Optimization of treatment for Helicobacter pylori-associated diseases. Vrach = Physician, 2012, no. 1, pp. 36–38. (In Russ.)]
- Цапиева А.Н., Боровкова Е.А., Карасева А.Б., Алиева Е.В., Суворов А.Н. Разработка метода идентификации индигенных лактобацилл кишечника при создании аутопробиотиков // Вопросы детской диетологии. 2019. Т. 17, № 3, pp. 52–59. [Tsapieva A.N., Borovkova E.A., Karaseva A.B., Alieva E.V., Suvorov A.N. Development of a method for identification of indigenous gut lactobacilli in the creation of autoprobiotics. Voprosy detskoi dietologii = Pediatric Nutrition, 2019, vol. 17, no. 3, pp. 52–59. (In Russ.)] doi: 10.20953/1727-5784-2019-3-52-59
- Boonyaritichaikij S., Kuwabara K., Nagano J., Kobayashi K., Koga Y. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. Helicobacter, 2009, vol. 14, no. 3, pp. 202–207. doi: 10.1111/j.1523-5378.2009.00675.x
- Canducci F., Cremonini F., Armuzzi A., Di Caro S., Gabrielli M., Santarelli L., Nista E., Lupascu A., De Martini D., Gasbarrini A. Probiotics and Helicobacter pylori eradication. Dig. Liver. Dis., 2002, vol. 34, suppl. 2, pp. S81–S83. doi: 10.1016/s1590-8658(02)80172-4
- Dore M.P., Cuccu M., Pes G.M., Manca A., Graham D.Y. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern. Emerg. Med., 2014, vol. 9, no. 6, pp. 649–654. doi: 10.1007/s11739-013-1013-z
- Ermolenko E.I., Abdurasulova I.N., Kotyleva M.P., Svirido D.A., Matsulevich A.V., Karaseva A.B. Effects of indigenous enterococci on the intestinal microbiota and the behavior of rats. Neurosci. Behav. Physiol., 2018, vol. 48, no. 4, pp. 496–505. doi: 10.1007/s11055-018-0591-7
- Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr., 2005, vol. 94, no. 12, pp. 1747–1751. doi: 10.1111/j.1651-2227.2005.tb01848.x
- Losurdo G., Cubisino R., Barone M., Principi M., Leandro G., Ierardi E., Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol., 2018, vol. 24, no. 1, pp. 139–149. doi: 10.3748/wjg.v24.i1.139
- Lü M., Yu S., Deng J., Yan Q., Yang C., Xia G., Zhou X. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One, 2016, vol. 11, no. 10: e0163743. doi: 10.1371/journal.pone.0163743
- Malfertheiner P., Megraud F., O’Morain C.A., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J.; European Helicobacter Study Group. Management of Helicobacter pylori infection — the Maastricht IV/Florence Consensus Report. Gut, 2012, vol. 61, no. 5, pp. 646–664. doi: 10.1136/gutjnl-2012-302084
- Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut., 2017, vol. 66, no. 1, pp. 6–30. doi: 10.1136/gutjnl-2016-312288
- Molina-Infante J., Gisbert J.P. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Rev. Esp. Enferm. Dig., 2013, vol. 105, no. 8, pp. 441–444. doi: 10.4321/s1130-01082013000800001
- Rosania R., Minenna M.F., Giorgio F., Facciorusso A., De Francesco V., Hassan C., Panella C., Ierardi E. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm. Allergy Drug Targets., 2012, vol. 11, no. 3, pp. 244–249. doi: 10.2174/187152812800392698
- Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis. Medicine (Baltimore), 2019, vol. 98, no. 15: e15180 doi: 10.1097/MD.0000000000015180
- Suvorov A., Karaseva A., Kotyleva M., Kondratenko Y., Lavrenova N., Korobeynikov A., Kozyrev P., Kramskaya T., Leontieva G., Kudryavtsev I., Guo D., Lapidus A., Ermolenko E. Autoprobiotics as an approach for restoration of personalised microbiota. Front. Microbiol., 2018, no. 9: 1869. doi: 10.3389/fmicb.2018.01869
- Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther., 2010, vol. 32, no. 9, pp. 1069–1079. doi: 10.1111/j.1365-2036.2010.04457.x
- Wang F., Feng J., Chen P., Liu X., Ma M., Zhou R., Chang Y., Liu J., Li J., Zhao Q. Probiotics in Helicobacter pylori eradication therapy: systematic review and network meta-analysis. Clin. Res. Hepatol. Gastroenterol., 2017, vol. 41, no. 4, pp. 466–475. doi: 10.1016/j.clinre.2017.04.004
- Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J. Gastroenterol., 2015, vol. 21, no. 14, pp. 4345–4357. doi: 10.3748/wjg.v21.i14.4345
Supplementary files
